Cost effectiveness of letrozole versus anastrozole in postmenopausal women with HR+ early-stage breast cancer

References

• The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57
   PubMed Web of Science ®Google Scholar
• Coates AS, Keshaviah A, Thürlimann B, et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for post-menopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007;25:486-92
   PubMed Web of Science ®Google Scholar
• ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2004;365:60-2
   Web of Science ®Google Scholar
• The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003;98:1802-10
   PubMed Web of Science ®Google Scholar
• The ATAC Trialists’ Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9
   PubMed Web of Science ®Google Scholar
• Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-29
   PubMed Web of Science ®Google Scholar
• Carlson RW, Brown E, Burstein HJ, et al. NCCN Task Force report: adjuvant therapy for breast cancer. J Natl Compr Canc Netw 2006;4(Suppl 1):S1-26
   PubMedGoogle Scholar
• The BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361:766-76
   PubMed Web of Science ®Google Scholar
• The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45-53
   PubMed Web of Science ®Google Scholar
• Delea TE, Karnon J, Sofrygin O, et al. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer 2007;7:608-18
   PubMed Web of Science ®Google Scholar
• Locker GY, Mansel R, Cella D, et al. ATAC Trialists’ Group. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat 2007;106:229-38. Epub 2007 Jan 24
   PubMed Web of Science ®Google Scholar
• Chapman RH, Benner JS, Girase P, et al. Generic and therapeutic statin switches and disruptions in therapy. Curr Med Res Opin 2009;25:1247-60
   PubMed Web of Science ®Google Scholar
• Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making 1993;13:322-38
   PubMed Web of Science ®Google Scholar
• Delea TE, Karnon J, Sofrygin O, et al. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Clin Breast Cancer 2007;7:608-18
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276:1253-8
   PubMed Web of Science ®Google Scholar
• Regan MM, Colleoni M, Giobbie-Hurder A, et al.; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjusting for selective crossover in analyses of letrozole versus tamoxifen in the BIG 1–98 trial. Presentation at San Antonio Breast Cancer Symposium, December 10, 2009 Abstract 16
   Google Scholar
• Howell A, Forbes J, Cuzick J. on behalf of the ATAC investigators. Initial adjuvant therapy with anastrozole – early- and late-event data from the Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial in the hormone-responsive population. Poster presented at the 11th St. Gallen Breast Cancer Conference, St Gallen, Switzerland, 11--14 March 2009
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
   PubMed Web of Science ®Google Scholar
• Partridge A, LaFountain A, Mayer E et al. Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 2008;26:556-62
   PubMed Web of Science ®Google Scholar
• Van Wijk BL, Klungel OH, Heerdink ER, et al. Generic substitution of antihypertensive drugs: does it affect adherence?. Ann Pharmacother 2006;40:15-20
   PubMed Web of Science ®Google Scholar
• Tierney JF, Stewart LA, Ghersi D, et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16
   PubMed Web of Science ®Google Scholar
• Arias E. United States Life Table, 2004. Nat Vital Stat Rep 56:1-39, 2007
   Google Scholar
• Leading causes of death in females: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2004. Available at: http://www.cdc.gov/women/lcod.htm [Last accessed 5 February 2010]
   Google Scholar
• Mouridsen H, Gershanovich M, Sun Y, et al. Phase-III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-9
   PubMed Web of Science ®Google Scholar
• Drug Topics Red Book. Oradell, NJ: Thomson Healthcare Inc., 2009
   Google Scholar
• Drug Topics Red Book. Oradell, NJ: Thomson Healthcare, Inc., 2007
   Google Scholar
• Drug Topics Red Book. Oradell, NJ: Thomson Healthcare, Inc., 2008
   Google Scholar
• Lamerato L, Havstad S, Gandhi S, et al. Economic burden associated with breast cancer recurrence: findings from a retrospective analysis of health system data. Cancer 2006;106:1875-82
   PubMed Web of Science ®Google Scholar
• FY 2004 PPS Payment Impact File: U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, 2008. Available at: http://www.cms.hhs.gov/AcuteInpatientPPS/HIF/list.asp#TopofPage [Last accessed 5 February 2010]
   Google Scholar
• Consumer Price Index: U.S. Bureau of Labor Statistics, 2009. Available at: http://www.bls.gov/data/ [Last accessed 9 June 2010]
   Google Scholar
• Sorensen S, Brown R, Benedict A, et al. Patient-rated utilities in postmenopausal early breast cancer: a cross country comparison. Contributed podium presentations. Value Health 2004;7:637-57
   PubMedGoogle Scholar
• Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health 2005;8:1-2
   PubMed Web of Science ®Google Scholar
• Shaw J, Zachry W. Application of probabilistic sensitivity analysis in decision analytic modeling. Practical Pharmacoecon 2002;37:38-9
   Google Scholar
• Fryback D, Dasbach E, Klein R, et al. The Beaver Dam health outcomes study: initial catalog of health state quality factors. Med Decis Making 1993;13:89-102
   PubMed Web of Science ®Google Scholar
• Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: In search of a standard. Med Decis Making 2000;20:332-42
   PubMed Web of Science ®Google Scholar
• Ubel PA, Hirth RA, Chernew ME, et al. What is the price of life and why doesn’t it increase at the rate of inflation. Arch Intern Med 2003;163:1637-41
   PubMed Web of Science ®Google Scholar
• Glenny AM, Altman DG, Song F, et al. International Stroke Trial Collaborative Group. Indirect comparisons of competing interventions. Health Technol Assess 2005;9:1-134, iii-iv
   PubMed Web of Science ®Google Scholar
• Claxton K. The irrelevance of inference: A decision-making approach to the stochastic evaluation of health care technologies. J Health Econ 1999;18:341-64
   PubMed Web of Science ®Google Scholar
• Trippoli S, Messori A. Cost effectiveness of sunitinib. J Clin Oncol 2008;26:5829
   PubMed Web of Science ®Google Scholar
• Crean SM, Reynolds M, Motabar S, et al. Discontinuation rates of adjuvant letrozole or anastrozole in breast cancer patients in an electronic medical record database observational study. The 2007 ASCO Breast Cancer Symposium Proceedings, Chicago, IL, June 1--5, 2007 (abstr 229)
   Google Scholar
• Delea TE, Karnon J, Smith RE, et al. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care 2006;12:374-86
   PubMed Web of Science ®Google Scholar
• El Ouagari K, Karnon J, Delea T, et al. Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat 2007;101:37-49. Epub 2006 Jul 4
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry bioavailability and bioequivalence studies for orally administered drug products — general considerations. July 2002 http://www.fda.gov/cder/guidance/index.htm
   Google Scholar
• Davit BM, Nwakama PE, Buehler GJ. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 2009;43:1583-97
   PubMed Web of Science ®Google Scholar